Stockscreener 앱 받기
13.79
1.10%
0.15
시간 외 거래:
13.74
-0.05
-0.36%
전일 마감가:
$13.64
열려 있는:
$13.6
하루 거래량:
853.72K
Relative Volume:
0.62
시가총액:
$1.15B
수익:
$31.37M
순이익/손실:
$-231.96M
주가수익비율:
-4.3595
EPS:
-3.1632
순현금흐름:
$-243.39M
1주 성능:
-1.71%
1개월 성능:
-6.19%
6개월 성능:
+4.08%
1년 성능:
+122.78%
1일 변동 폭
$13.25
$13.97
1주일 범위
$12.90
$14.10
52주 변동 폭
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
명칭
Eyepoint Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
13.79 | 1.14B | 31.37M | -231.96M | -243.39M | -3.1632 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Inc 주식(EYPT)의 최신 뉴스
Behavioral Patterns of EYPT and Institutional Flows - Stock Traders Daily
Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients - Traders Union
EyePoint (EYPT) surges 15.2%: Is this an indication of further gains? - MSN
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 earnings call transcript - MSN
Risk Hedge: What is the long term forecast for EyePoint Pharmaceuticals Inc stock2026 Geopolitical Influence & Safe Entry Point Identification - baoquankhu1.vn
EyePoint Pharmaceuticals Q4 2025 earnings preview - MSN
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment - AOL.com
Insider Buying: Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys 1,500 Shares of Stock - MarketBeat
Eyepoint (EYPT) CEO Duker buys $19,723 in company stock - Investing.com
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus - TipRanks
Guggenheim reiterates EyePoint stock rating on Duravyu safety data By Investing.com - Investing.com Canada
Guggenheim reiterates EyePoint stock rating on Duravyu safety data - Investing.com
EyePoint (EYPT) Issues Stock Options to New Employees as Hiring Incentives - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint gives new hires 20,000 stock options, $13.20 strike - Stock Titan
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com Nigeria
Parkman Healthcare Partners Acquires New Stake in EyePoint Pharmaceuticals - Intellectia AI
Suvretta Capital Management LLC Sells 611,376 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Rosalind Advisors Inc. Acquires Shares of 650,000 Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com Nigeria
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 9.1%Here's Why - MarketBeat
Jefferies Financial Group Inc. Purchases Shares of 140,000 Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Winners Losers: Should I hold or sell EyePoint Pharmaceuticals Inc now2026 Review & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
EyePoint files automatic mixed securities shelf - MSN
H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress - Investing.com Nigeria
J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Aug Breakouts: Can EyePoint Pharmaceuticals Inc expand its profit margins2026 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities - The Globe and Mail
EyePoint Pharmaceuticals Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations - Markets Mojo
EyePoint (EYPT) Sees Target Price Raise by Citigroup to $35 | EY - GuruFocus
Citigroup Boosts Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $35.00 - MarketBeat
EyePoint stock rating maintained at Outperform by Mizuho - Investing.com
EyePoint stock rating maintained at Outperform by Mizuho By Investing.com - Investing.com South Africa
What is HC Wainwright's Estimate for EYPT Q1 Earnings? - MarketBeat
EyePoint Reports Fourth-Quarter and Full-Year 2025 Financial Results, Provides Corporate Update - VisionMonday.com
(EYPT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
Eyepoint Pharmaceuticals, Inc. $EYPT Holdings Trimmed by Blue Owl Capital Holdings LP - MarketBeat
EyePoint (EYPT) Q4 2025 Earnings Call Transcript - AOL.com
EyePoint (EYPT) CFO gifts 10,000 shares, including family trust holdings - Stock Titan
Decoding EyePoint Inc (EYPT): A Strategic SWOT Insight - GuruFocus
Is It Too Late To Consider EyePoint (EYPT) After Its 173% One Year Surge? - Yahoo Finance
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $30.00 - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating - marketscreener.com
EyePoint (EYPT) Analyst Rating Update: Price Target Increased to $30 | EYPT Stock News - GuruFocus
EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT) - Seeking Alpha
Chardan Capital Raises Price Target for EYPT to $29.00, Maintains Buy Rating | EYPT Stock News - GuruFocus
Eyepoint Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):